Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01646762 · OUTCOME

Survival Time

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2017-10-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Time from registration to death due to any cause, assessed up to 3 years

What was measured

Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.

Groups in this outcome

Treatment (Chemotherapy)

Patients receive 100 mg nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 (with 1 week rest). Treatment repeats every 28 days for up to 12 courses/cycles in the absence of disease progression or unacceptable toxicity. After 12 cycles, continued treatment is at the discretion of the investigator until evidence of disease progression. Paclitaxel Albumin-Stabilized Nanoparticle Formulation: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Chemotherapy)13

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Chemotherapy)3.7Not reported1.7NAThe upper limit of the 95% confidence interval was not reached.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        The upper limit of the 95% confidence interval was not reached.
        group Id
        OG000
        lower Limit
        1.7
        upper Limit
        NA
        value
        3.7
denoms
  1. counts
    1. group Id
      OG000
      value
      13
    units
    Participants
description
Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive 100 mg nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 (with 1 week rest). Treatment repeats every 28 days for up to 12 courses/cycles in the absence of disease progression or unacceptable toxicity. After 12 cycles, continued treatment is at the discretion of the investigator until evidence of disease progression. Paclitaxel Albumin-Stabilized Nanoparticle Formulation: Given IV
    id
    OG000
    title
    Treatment (Chemotherapy)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Time from registration to death due to any cause, assessed up to 3 years
title
Survival Time
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice